Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aims: Multiple myeloma (MM) is a hematological cancer associated with increased clonal malignant plasma cells. Growth differentiation factor 15 (GDF 15) is a protein that is highly expressed in the bone marrow mesenchymal stem cells of patients with MM. This study investigated whether the clinical stage of the disease, treatment response and survival are affected by pretreatment serum GDF 15 levels.
Methods: Serum GDF 15 levels were measured in 35 newly diagnosed MM patients and 27 healthy controls. The correlation between serum GDF 15 levels and various clinical and laboratory parameters was analyzed.
Results: The study demonstrated significantly higher levels of GDF 15 in MM patients. There was a negative correlation between GDF 15 levels, hemoglobin and albumin levels, and a positive correlation between GDF 15 levels, CRP, creatinine, β-2-microglobulin and stage. GDF 15 levels were lower in patients who could receive autologous stem cell transplantation compared to other groups, representing a statistically significant difference. However, in the survival analyses, GDF 15 level did not have an impact on survival.
Conclusion: High serum levels of GDF 15 may indicate a poor treatment response. Our study supports the prognostic value of GDF 15 in MM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000354835 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inflammatory pathways in vascular disease are the focus of intense interest. Accumulating evidence suggests a role for GDF-15 in the atherosclerotic process. In this study we measured circulating levels of IL-6 and GDF-15 in a cohort of 20 vascular surgical patients with atherosclerotic disease presenting for surgical revascularisation and in a similar number of age-matched healthy volunteers.
View Article and Find Full Text PDFSerum levels of GDF-15, betatrophin, TNF-α and IL-6 in diabetic patients with and without diabetic complications.
Saudi Med J
September 2025
From the Department of Family Medicine (Yılmaz), School of Medicine, Dicle University, Diyarbakir, Department of Molecular Biology and Genetics (Kaymaz), Faculty of Arts and Sciences, Nevşehir, Hacı Bektaş Veli University, Nevşehir, Department of Family Medicine (Yakar, Gömleksiz, Önalan, Gü
Objectives: To investigate serum levels of growth differentiation factor 15 (GDF-15), inflammatory biomarkers, and betatrophin in individuals with diabetes mellitus, both with and without complications.
Methods: A cross-sectional analysis was conducted involving patients with diabetes. Participants were categorized into 3 groups: Group 1 (30 healthy individuals without diabetes), Group 2 (30 diabetic patients without complications), and Group 3 (30 diabetic patients with complications).
The role of FGF21 in the metabolic adjustments required for exercise capacity.
Life Sci
August 2025
Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. Electronic address:
Fatigue is one of the most common and persistent symptoms experienced by patients with various medical conditions. It is characterized by its enduring nature, lack of improvement after a good night's sleep, and interference with daily functioning. The mechanisms behind fatigue remain controversial.
View Article and Find Full Text PDFAssessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.
J Card Fail
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
Background: Randomized trials remain the standard for evaluating novel therapies. Primary endpoint(s) risk heterogeneity may dilute treatment efficacy. The 5-step stratified testing and amalgamation routine (5-STAR) methodology helps address these limitations.
View Article and Find Full Text PDFDynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.
J Clin Med
August 2025
Department of Internal Medicine II, Paracelsus Medical University, 5020 Salzburg, Austria.
Despite improvements in medical therapy, heart failure with reduced ejection fraction (HFrEF) is a major burden on the healthcare system and remains a leading cause of death with a 5-year mortality rate of more than 60%. Novel therapeutic agents such as angiotensin-receptor-neprilysin-inhibitors (ARNIs) lead to significant improvement in clinical outcomes. Optimal therapy monitoring under these novel drugs is crucial for improving the outcome.
View Article and Find Full Text PDF